cmAngio® vs Imbio RV/LV Software
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to integrate cardiovascular risk assessment into routine breast screening for women. This AI-powered tool is ideal for identifying Breast Arterial Calcifications (BAC) on mammograms, providing valuable insights into a patient's cardiovascular health without requiring additional radiation or procedures. It helps clinicians flag women who may benefit from further cardiovascular evaluation based on existing imaging data.
View cmAngio® →Choose Imbio RV/LV Software if…
Choose Imbio RV/LV Software if you require automated, rapid assessment of right and left ventricular diameters from CTPA scans, especially for risk stratification in patients with suspected pulmonary conditions like pulmonary embolism. This tool is best suited for clinical environments where quick and objective RV/LV ratio measurements are crucial for guiding urgent treatment decisions and managing patients with acute pulmonary issues. It streamlines the analysis of CTPA images to provide critical cardiac insights efficiently.
View Imbio RV/LV Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Imbio RV/LV Software |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based, Locally virtualized (virtual machine, Docker), or through partners like Aidoc, Blackford Analysis, and Philips Healthcare. [9, 27] |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio RV/LV SoftwareTool B offers a fully automated workflow that requires no user intervention after scan completion, streamlining the process for clinicians. While Tool A boasts quick installation and DICOM compatibility, Tool B's minimal user interface and automated processing integrate more seamlessly into existing radiological workflows, reducing manual steps.
Clinical Value
cmAngio®Tool A provides significant clinical value by repurposing routine mammograms to detect Breast Arterial Calcifications (BAC), offering insights into cardiovascular health and aiding early risk assessment for coronary heart disease, the leading cause of death in women. This leverages an existing, non-invasive screening for a critical, often under-recognized health risk without additional radiation.
Pricing & Value
Imbio RV/LV SoftwareTool B offers greater transparency in its pricing model, clearly stating it is subscription-based and dependent on the number of analyses or installations. Tool A's pricing is opaque, requiring direct contact with the vendor, which makes it harder for potential buyers to assess its value proposition upfront, despite mentions of potential no-cost offers.
Enterprise Readiness
Imbio RV/LV SoftwareTool B demonstrates superior enterprise readiness with explicit third-party HIPAA compliance certification and a clear statement of having a Business Associate Agreement (BAA). Furthermore, it offers highly flexible deployment options, including cloud, on-premise, and integration with multiple partner platforms, accommodating diverse IT infrastructures and compliance needs.
Innovation
cmAngio®Tool A exhibits a higher degree of innovation by applying AI to extract novel cardiovascular risk insights (Breast Arterial Calcifications) from a widely performed, routine breast cancer screening mammogram. This cross-disciplinary application of AI to repurpose existing data for a different, yet highly impactful, health concern is particularly innovative.
Support & Docs
Imbio RV/LV SoftwareTool B wins this dimension as its user manual is explicitly mentioned and linked on its support documentation page, indicating a more transparent and accessible approach to providing product information and support resources. Tool A only vaguely refers to an 'Operator's Manual' without providing direct access or specific support channels.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Imbio RV/LV Software |
|---|---|---|
| Name | cmAngiou00ae | Imbio RV/LV Software |
| Company | CureMetrix | Imbio |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism. |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | Automated measurement of right and left ventricular diameters |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Calculation and reporting of RV/LV ratio |
| Key Feature 3 | Provides visualization of BAC location on a scorecard | Artificial intelligence algorithm for ventricle identification and measurement |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Imbio RV/LV Software.